Ishara Investments LP Makes New Investment in Agios Pharmaceuticals, Inc. $AGIO

Ishara Investments LP purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $817,000. Ishara Investments LP owned approximately 0.05% of Agios Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Creative Planning raised its position in Agios Pharmaceuticals by 2.2% in the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock worth $527,000 after acquiring an additional 280 shares in the last quarter. Assetmark Inc. raised its holdings in Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 362 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Agios Pharmaceuticals by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock worth $4,393,000 after buying an additional 512 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 588 shares during the period. Finally, CANADA LIFE ASSURANCE Co raised its holdings in Agios Pharmaceuticals by 3.4% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock worth $796,000 after buying an additional 662 shares during the period.

Wall Street Analyst Weigh In

AGIO has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. HC Wainwright cut their price objective on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Bank of America cut their price objective on Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, May 29th. The Goldman Sachs Group boosted their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Finally, JPMorgan Chase & Co. cut their price objective on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $40.89.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 3,262 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $113,224.02. Following the transaction, the insider owned 46,829 shares of the company’s stock, valued at $1,625,434.59. The trade was a 6.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James William Burns sold 3,280 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,848.80. Following the transaction, the insider directly owned 49,306 shares in the company, valued at approximately $1,711,411.26. This trade represents a 6.24% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 12,623 shares of company stock worth $438,144. Insiders own 5.40% of the company’s stock.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $33.08 on Thursday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The stock’s 50-day moving average is $29.17 and its two-hundred day moving average is $28.58. The stock has a market cap of $1.97 billion, a PE ratio of -4.56 and a beta of 0.59.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The company had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $13.30 million. The business’s revenue for the quarter was up 137.7% on a year-over-year basis. On average, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.28 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.